Effects of canagliflozin on human myocardial redox signalling: clinical implications

2021111 citationsJournal Articlehybrid Open Access

Authors

Hidekazu Kondo · University of Oxford

Ioannis Akoumianakis · University of Oxford

Ileana Badi · John Radcliffe Hospital

Nadia Akawi · University of Oxford

Christos P. Kotanidis · John Radcliffe Hospital

Murray Polkinghorne · John Radcliffe Hospital

Ilaria Stadiotti ·

Abstract

We demonstrate for the first time that canagliflozin suppresses myocardial NADPH oxidase activity and improves NOS coupling via SGLT1/AMPK/Rac1 signalling, leading to global anti-inflammatory and anti-apoptotic effects in the human myocardium. These findings reveal a novel mechanism contributing to the beneficial cardiac effects of canagliflozin.

Topics & Keywords

Diabetes Treatment and Management Cardiovascular Function and Risk Factors Heart rate and cardiovascular health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal

Volume 42, Issue 48, pp. 4947-4960

DOI: 10.1093/eurheartj/ehab420

Field-Weighted Citation Impact: 13.21